Cumberland Pharmaceuticals Inc.
General ticker "CPIX" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $59.7M (TTM average)
Cumberland Pharmaceuticals Inc. follows the US Stock Market performance with the rate: 51.6%.
Estimated limits based on current volatility of 4.2%: low 7.09$, high 7.70$
Factors to consider:
- Company pays dividends (irregularly): last record date 2026-07-23, amount 1.50$ (Y20.89%)
- Total employees count: 93 (+2.2%) as of 2025
- Countries other than US accounted for 7.1% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Geopolitical risks, Regulatory and compliance, Market competition, Cybersecurity threats, Labor/talent shortage/retention
- Current price 89.6% above estimated high
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.65$, 3.79$]
- 2026-12-31 to 2027-12-31 estimated range: [1.32$, 3.14$]
Financial Metrics affecting the CPIX estimates:
- Positive: with PPE of 37.6 at the end of fiscal year the price was low
- Positive: 6.77 < Operating cash flow per share per price, % of 7.98
- Positive: -13.52 < Operating profit margin, % of -5.90
- Positive: Industry inventory ratio change (median), % of -0.31 <= 0
- Positive: Inventory ratio change, % of 2.71 <= 4.02
- Positive: 25.20 < Shareholder equity ratio, % of 32.39 <= 34.41
- Positive: -51.61 < Industry operating profit margin (median), % of -17.91
- Positive: -6.44 < Industry operating cash flow per share per price (median), % of -1.98
Short-term CPIX quotes
Long-term CPIX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $39.55MM | $37.87MM | $44.52MM |
| Operating Expenses | $49.11MM | $44.30MM | $47.31MM |
| Operating Income | $-9.55MM | $-6.43MM | $-2.79MM |
| Non-Operating Income | $3.27MM | $-0.03MM | $-0.03MM |
| Interest Expense | $0.67MM | $0.61MM | $0.50MM |
| R&D Expense | $5.83MM | $4.82MM | $5.57MM |
| Income(Loss) | $-6.28MM | $-6.47MM | $-2.82MM |
| Taxes | $0.05MM | $-0.02MM | $0.04MM |
| Other Income(Loss) | $0.00MM | $0.00MM | $-0.01MM |
| Net Income(Loss)* | $-6.28MM | $-6.48MM | $-2.84MM |
| Stockholders Equity | $29.60MM | $22.85MM | $24.88MM |
| Inventory | $4.61MM | $4.00MM | $6.23MM |
| Assets | $81.78MM | $75.58MM | $76.82MM |
| Operating Cash Flow | $6.09MM | $-0.61MM | $4.93MM |
| Capital expenditure | $0.45MM | $0.18MM | $0.10MM |
| Investing Cash Flow | $-0.11MM | $0.06MM | $-4.71MM |
| Financing Cash Flow | $-7.42MM | $0.20MM | $-6.75MM |
| Earnings Per Share** | $-0.44 | $-0.46 | $-0.19 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.